Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseGraft-versus-Host Disease, chronicSubgroupICD10T86.05+T86.06+T86.07+MeSHGraft vs Host DiseaseSequenceChemotherapyChemo-substanceRuxolitinibChemo-substanceRuxolitinibChemo-substanceRuxolitinibChemo-substanceRuxolitinibNo. Substances1 RadiotherapySupportive therapySupportive substanceBelumosudilDexamethasoneGranisetronSupportive substanceBelumosudilDexamethasoneGranisetronSupportive substanceBelumosudilDexamethasoneGranisetronSupportive substanceBelumosudilDexamethasoneGranisetronNo. Substances3Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRefractory diseaseTherapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlArthalgiaCMV Infection (asympt. + sympt.)DiarrheaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)HeadacheHyperglycemiaHypertensionHypokalemiaIncrease AminotransferasesInfectionsNeutropeniaPneumoniaThrombocytopenia below 50 000/µlUpper Respiratory Tract Infection only studiesPublicationAuthorCutler CZeiser RDiseaseChronische Graft-versus-Host-Erkrankung moderat oder schwer, mind. 2 VortherapienChronische Graft-versus-Host-Erkrankung moderat oder schwer, steroidrefraktär oder steroidabhängigOriginDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, ROCKstar StudyUniversity Medical Center Freiburg, Freiburg, Germany, REACH3 TrialProtocols in Revision 2 protocols foundBelumosudil 200, graft-versus-host disease, chronic (PID3038 V1.0)Ruxolitinib 10, Graft-versus-Host Disease, chronic (PID2109 V1.0)
